Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Upstream Bio, Inc.NASDAQ: UPB
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI falls 72.8% from a year ago
Accumulated OCI stood at $100K at the end of Q1 FY2026, down 72.8% from a year earlier and down 81.1% from the prior quarter.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -72.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 530K USD
- Year-over-year change
- +2220.0%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 530K | +2220.0% |
| FY2024 | 2024-12-31 | (25K) | -219.0% |
| FY2023 | 2023-12-31 | 21K | — |
| FY2022 | 2022-12-31 | 0 | — |
Accumulated OCI vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -72.8% is the 3rd highest of 10, against a peer median of -122.7%.
- Accumulated OCI amounts to 0.0% of total assets for UPB, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €56.99M EUR | +20.5% | +35.7% | 19.3% | |
UPBUpstream Bio, Inc. | Mar 2026 | $100K USD | -72.8% | — | 0.0% |
| Mar 2026 | $11K USD | -97.9% | — | 0.0% | |
| Sep 2026 | -$179K USD | -122.0% | — | 0.0% | |
| Mar 2026 | -$240K USD | -122.7% | — | 0.0% | |
| Mar 2026 | -$254K USD | -24.5% | — | 0.0% | |
| Mar 2026 | -$377K USD | -367.4% | — | 0.1% | |
| Jun 2026 | -$1.55M USD | -852.8% | — | 0.2% | |
| Mar 2026 | -$5.07M USD | -415.5% | — | 0.5% | |
| Sep 2026 | -$5.38M USD | -780.4% | — | 0.5% | |
| Peer median (excluding UPB) | — | -122.7% | +35.7% | 0.1% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.